Yank are you saying that our results bettered Humira's results even though MESO trial tested patients that failed 1,2 or more than 3 drug treatments?
Are you saying our trial results (although small in number) were comparable or better than Abbvies results.... while showing far less side effects?
Obviously this is ground breaking on so many levels.
Silvu did not want to rock the boat and go for first line approval. Smart
This trial will allow the drug to be used after standard of care.... for now. He is playing nice for a deal/partnership
Fantastic results that have shown the longevity of these cells.
Imagine if they could give 2 or 3 doses when it is warranted
Yank are you saying that our results bettered Humira's results...
-
- There are more pages in this discussion • 30 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
95.0¢ |
Change
-0.015(1.55%) |
Mkt cap ! $1.084B | |||
| Open | High | Low | Value | Volume |
| 96.5¢ | 96.5¢ | 94.5¢ | $2.433M | 2.552M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 72431 | 94.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 95.0¢ | 20225 | 5 |
View Market Depth
| Last trade - 16.10pm 27/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |